Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A dose escalation study of ALT-803 in patients relapsed after allogeneic hematopoietic cell transplantation

Trial Profile

A dose escalation study of ALT-803 in patients relapsed after allogeneic hematopoietic cell transplantation

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Dec 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ALT 803 (Primary) ; ALT 803 (Primary)
  • Indications Acute myeloid leukaemia; Diffuse large B cell lymphoma; Multiple myeloma; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 20 Dec 2018 According to The American Society of Hematology media release, data form this trial was published in the journal Blood.
    • 26 Dec 2017 New trial record
    • 12 Dec 2017 Results of complete study presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top